Learn more about the drugs and therapies developed at NYU that are currently in or on their way to the market.

Therapeutics Pipeline

Product
Licensee
Indication
Preclinical
Phase I
Phase II
Phase III
Approved
LORBRENA® (lorlatinib)
Licensee: Pfizer, Inc.
Indication: Non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene and that has spread to other parts of the body
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 100%
Mosquirix™ (RTS,S)*
Licensee: GSK
Indication: Malaria (vaccine)
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 100%
ORACEA® (doxycycline, USP)
Licensee: Galderma
Indication: Inflammatory lesions of rosacea
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 100%
PROMACTA® (eltrombopag)
Licensee: GSK
Indication: Thrombocytopenia in patients with chronic immune thrombocytopenic purpura that did not get better with other treatment
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 100%
REMICADE® (infliximab)
Licensee: Janssen
Indication: Crohn’s disease, Ulcerative colitis, Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis, Plaque psoriasis
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 100%
SUTENT® (sunitinib malate)
Licensee: Pfizer Inc.
Indication: Gastrointestinal stromal tumor, Renal cell carcinoma, Pancreatic cancer
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 100%
XALKORI​​​​​​® (crizotinib)​
Licensee: Pfizer Inc.
Indication: Metastatic non-small cell lung cancer (NSCLC) where tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 100%
ZINECARD® (dexrazoxane)
Licensee: Pfizer Inc.
Indication: Reduction of incidence and severity of cardiac dysfunction associated with anthracycline use
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 100%
Brexpiprazole
Licensee: Lundbeck
Indication: Agitation in Alzheimer’s Disease
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 80%
HyBryte™
Licensee: Soligenix
Indication: Cutaneous T-cell lymphoma
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 80%
Generx 
Licensee: Gene Bio Therapeutics
Indication: Refractory angina
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 80%
ARGX-119
Licensee: argenx
Indication: Neuromuscular Indications
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 40%
LYT-200
Licensee: PureTech
Indication: Cancer indications, including: Pancreatic ductal adenocarcinoma, Colorectal cancer, Cholangiocarcinoma
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 40%
TBD
Licensee: Nostrum
Indication: Pulmonary fibrosis
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 40%
TBD
Licensee: Empriver
Indication: Alzheimer’s disease
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 40%
TBD
Licensee: Janssen
Indication: Oncolytic virus
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 40%
LYT-210
Licensee: PureTech
Indication: Cancer
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 20%
TBD
Licensee: Janssen
Indication: Staph infection
Preclinical
Phase I
Phase II
Phase III
Approved
Progress: 20%
Product Licensee Indication
Preclinical
Phase I
Phase II
Phase III
Approved
LORBRENA® (lorlatinib) Pfizer, Inc. Non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene and that has spread to other parts of the body
Progress: 100%
Mosquirix™ (RTS,S)* GSK Malaria (vaccine)
Progress: 100%
ORACEA® (doxycycline, USP) Galderma Inflammatory lesions of rosacea
Progress: 100%
PROMACTA® (eltrombopag) GSK Thrombocytopenia in patients with chronic immune thrombocytopenic purpura that did not get better with other treatment
Progress: 100%
REMICADE® (infliximab) Janssen Crohn’s disease, Ulcerative colitis, Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis, Plaque psoriasis
Progress: 100%
SUTENT® (sunitinib malate) Pfizer Inc. Gastrointestinal stromal tumor, Renal cell carcinoma, Pancreatic cancer
Progress: 100%
XALKORI​​​​​​® (crizotinib)​ Pfizer Inc. Metastatic non-small cell lung cancer (NSCLC) where tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive
Progress: 100%
ZINECARD® (dexrazoxane) Pfizer Inc. Reduction of incidence and severity of cardiac dysfunction associated with anthracycline use
Progress: 100%
Brexpiprazole Lundbeck Agitation in Alzheimer’s Disease
Progress: 80%
HyBryte™ Soligenix Cutaneous T-cell lymphoma
Progress: 80%
Generx  Gene Bio Therapeutics Refractory angina
Progress: 80%
ARGX-119 argenx Neuromuscular Indications
Progress: 40%
LYT-200 PureTech Cancer indications, including: Pancreatic ductal adenocarcinoma, Colorectal cancer, Cholangiocarcinoma
Progress: 40%
TBD Nostrum Pulmonary fibrosis
Progress: 40%
TBD Empriver Alzheimer’s disease
Progress: 40%
TBD Janssen Oncolytic virus
Progress: 40%
LYT-210 PureTech Cancer
Progress: 20%
TBD Janssen Staph infection
Progress: 20%

*Not FDA approved/Not available in the U.S. Mosquirix received a positive scientific opinion from the European Medicines Agency on the proposal for the vaccine to be used to vaccinate children aged 6 weeks to 17 months outside the European Union.